This company listing is no longer active
LIDDS (5LD) Stock Overview
A drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
5LD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
LIDDS AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.0004 |
| 52 Week Low | SEK 0.0002 |
| Beta | -0.27 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5LD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -3.3% |
| 1Y | n/a | -7.9% | -4.0% |
Return vs Industry: Insufficient data to determine how 5LD performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 5LD performed against the German Market.
Price Volatility
| 5LD volatility | |
|---|---|
| 5LD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 5LD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5LD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1 | Mats Wiking | www.liddspharma.com |
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments.
LIDDS AB (publ) Fundamentals Summary
| 5LD fundamental statistics | |
|---|---|
| Market cap | €316.29k |
| Earnings (TTM) | -€525.45k |
| Revenue (TTM) | n/a |
Is 5LD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5LD income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 3.05m |
| Gross Profit | -SEK 3.05m |
| Other Expenses | SEK 2.53m |
| Earnings | -SEK 5.58m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 26, 2026
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5LD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/16 10:58 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LIDDS AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethel Szpilman Luvall | Redeye |